Cytochrome P450-mediated arachidonic acid metabolism (CYP-AA metabolism)

Cytochrome P450-mediated arachidonic acid metabolism is a complex biochemical pathway that serves as the "third branch" of the arachidonic acid cascade, alongside the cyclooxygenase and lipoxygenase pathways [1, 15]. It involves the conversion of arachidonic acid into bioactive lipid mediators, primarily epoxyeicosatrienoic acids (EETs) and hydroxyeicosatetraenoic acids (HETEs), by various cytochrome P450 (CYP) enzymes [4, 10]. The CYP epoxygenases, such as the CYP2C and CYP2J isoforms, produce EETs, which generally exhibit vasodilatory, anti-inflammatory, and cardioprotective properties [7, 11]. Conversely, CYP ω-hydroxylases, such as the CYP4A and CYP4F isoforms, produce 20-HETE, a potent vasoconstrictor and pro-inflammatory agent [5, 9]. This pathway plays a pivotal role in the regulation of vascular tone, blood pressure, and renal function, and its dysregulation is implicated in the pathogenesis of hypertension, cardiovascular diseases, and chronic kidney disease [5, 15]. Pharmacological modulation of this pathway represents a promising therapeutic strategy, with approaches including the inhibition of 20-HETE synthesis or the stabilization of EETs using soluble epoxide hydrolase (sEH) inhibitors [15]. Additionally, certain drugs like fluconazole and resveratrol have been shown to modulate these enzymes, potentially offering repurposing opportunities for cardiorenal protection [2, 3]. However, targeting this pathway requires careful consideration of off-target effects on drug metabolism and potential impacts on tumor angiogenesis [7, 8].

Other names

CYP-dependent arachidonic acid metabolismThird pathway of arachidonic acid metabolismCytochrome P450 eicosanoid pathwayCYP-AA pathway

Modulation of bioactive eicosanoid levels, including the inhibition of 20-HETE synthesis and the stabilization of EETs, to regulate vascular tone and inflammatory signaling.